CN110075188A - 食用组合物及其制备方法 - Google Patents
食用组合物及其制备方法 Download PDFInfo
- Publication number
- CN110075188A CN110075188A CN201910440842.1A CN201910440842A CN110075188A CN 110075188 A CN110075188 A CN 110075188A CN 201910440842 A CN201910440842 A CN 201910440842A CN 110075188 A CN110075188 A CN 110075188A
- Authority
- CN
- China
- Prior art keywords
- parts
- edible composition
- preparation
- edible
- obtains
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 67
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 60
- 239000007788 liquid Substances 0.000 claims abstract description 48
- 239000000284 extract Substances 0.000 claims abstract description 44
- 241000255789 Bombyx mori Species 0.000 claims abstract description 32
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 29
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 29
- 239000009636 Huang Qi Substances 0.000 claims abstract description 29
- 241000245665 Taraxacum Species 0.000 claims abstract description 28
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 28
- 235000008434 ginseng Nutrition 0.000 claims abstract description 27
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 26
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 26
- 244000197580 Poria cocos Species 0.000 claims abstract description 20
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 20
- 239000000706 filtrate Substances 0.000 claims abstract description 16
- 238000001035 drying Methods 0.000 claims abstract description 8
- 241000208340 Araliaceae Species 0.000 claims abstract 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 239000006228 supernatant Substances 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 8
- 238000005057 refrigeration Methods 0.000 claims description 3
- 238000003860 storage Methods 0.000 claims description 3
- 238000002386 leaching Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 22
- 210000004185 liver Anatomy 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 20
- 229940079593 drug Drugs 0.000 abstract description 11
- 235000013305 food Nutrition 0.000 abstract description 8
- 230000035622 drinking Effects 0.000 abstract description 6
- 235000008216 herbs Nutrition 0.000 abstract description 6
- 239000003053 toxin Substances 0.000 abstract description 6
- 231100000765 toxin Toxicity 0.000 abstract description 6
- 230000010354 integration Effects 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 5
- 239000000049 pigment Substances 0.000 abstract description 5
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- 241000721047 Danaus plexippus Species 0.000 abstract description 4
- 230000001093 anti-cancer Effects 0.000 abstract description 4
- 239000003755 preservative agent Substances 0.000 abstract description 4
- 230000002335 preservative effect Effects 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- 238000012545 processing Methods 0.000 abstract description 2
- 238000004140 cleaning Methods 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 240000004371 Panax ginseng Species 0.000 description 20
- 230000006870 function Effects 0.000 description 17
- 206010028980 Neoplasm Diseases 0.000 description 14
- 201000011510 cancer Diseases 0.000 description 14
- 210000000952 spleen Anatomy 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 9
- 235000019634 flavors Nutrition 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 231100000614 poison Toxicity 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 5
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 5
- 244000000231 Sesamum indicum Species 0.000 description 5
- 235000003434 Sesamum indicum Nutrition 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 4
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 4
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 4
- 229960001231 choline Drugs 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000036737 immune function Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 229960002477 riboflavin Drugs 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 3
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 229930003471 Vitamin B2 Natural products 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 235000006533 astragalus Nutrition 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- -1 coumarin glucoside Chemical class 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000007096 poisonous effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 235000021251 pulses Nutrition 0.000 description 3
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 235000015961 tonic Nutrition 0.000 description 3
- 230000001256 tonic effect Effects 0.000 description 3
- 230000010415 tropism Effects 0.000 description 3
- 235000019164 vitamin B2 Nutrition 0.000 description 3
- 239000011716 vitamin B2 Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- XWMMEBCFHUKHEX-MRTCRTFGSA-N (+)-Taraxasterol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC[C@]1(C)[C@@H]2CC[C@H]2[C@@H]3[C@H](C)C(=C)CC[C@]3(C)CC[C@]21C XWMMEBCFHUKHEX-MRTCRTFGSA-N 0.000 description 2
- QMKPCZNFLUQTJZ-UHFFFAOYSA-N (4aR)-10c-Hydroxy-1t.2c.4ar.6at.6bc.9.9.12ac-octamethyl-(8atH.12btH.14acH.14btH)-docosahydro-picen Natural products CC1CCC2(C)CCC3(C)C(CCC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C QMKPCZNFLUQTJZ-UHFFFAOYSA-N 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- 101710191958 Amino-acid acetyltransferase Proteins 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- 208000031091 Amnestic disease Diseases 0.000 description 2
- 102000009042 Argininosuccinate Lyase Human genes 0.000 description 2
- 241001061264 Astragalus Species 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 241000222336 Ganoderma Species 0.000 description 2
- 241001480597 Ganoderma tsugae Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 244000241838 Lycium barbarum Species 0.000 description 2
- 235000015459 Lycium barbarum Nutrition 0.000 description 2
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241000222341 Polyporaceae Species 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 206010044302 Tracheitis Diseases 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 241000700647 Variola virus Species 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- FSLPMRQHCOLESF-UHFFFAOYSA-N alpha-amyrenol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)C(C)C5C4=CCC3C21C FSLPMRQHCOLESF-UHFFFAOYSA-N 0.000 description 2
- 230000006986 amnesia Effects 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- JFSHUTJDVKUMTJ-QHPUVITPSA-N beta-amyrin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C JFSHUTJDVKUMTJ-QHPUVITPSA-N 0.000 description 2
- QQFMRPIKDLHLKB-UHFFFAOYSA-N beta-amyrin Natural products CC1C2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C)CCC1(C)C QQFMRPIKDLHLKB-UHFFFAOYSA-N 0.000 description 2
- PDNLMONKODEGSE-UHFFFAOYSA-N beta-amyrin acetate Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4=CCC23C)C1(C)C PDNLMONKODEGSE-UHFFFAOYSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- ZZIALNLLNHEQPJ-UHFFFAOYSA-N coumestrol Chemical compound C1=C(O)C=CC2=C1OC(=O)C1=C2OC2=CC(O)=CC=C12 ZZIALNLLNHEQPJ-UHFFFAOYSA-N 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 235000012680 lutein Nutrition 0.000 description 2
- 239000001656 lutein Substances 0.000 description 2
- 229960005375 lutein Drugs 0.000 description 2
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 2
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000001473 noxious effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000000575 pesticide Substances 0.000 description 2
- 235000019175 phylloquinone Nutrition 0.000 description 2
- 239000011772 phylloquinone Substances 0.000 description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 2
- 229960001898 phytomenadione Drugs 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- NGFFRJBGMSPDMS-UHFFFAOYSA-N psi-Taraxasterol Natural products CC12CCC(O)C(C)(C)C1CCC1(C)C2CCC2C3C(C)C(C)=CCC3(C)CCC21C NGFFRJBGMSPDMS-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 210000004233 talus Anatomy 0.000 description 2
- HUTYZQWCTWWXND-NCTFTGAASA-N taraxasterol Natural products C[C@H]1[C@H]2C3=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)C[C@H](O)[C@@]2(C)CCC1=C HUTYZQWCTWWXND-NCTFTGAASA-N 0.000 description 2
- 229960000716 tonics Drugs 0.000 description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 2
- LTTQKYMNTNISSZ-MWTRTKDXSA-N (2S)-(-)-kurarinone Chemical compound C1([C@H]2OC=3C(C[C@@H](CC=C(C)C)C(C)=C)=C(O)C=C(C=3C(=O)C2)OC)=CC=C(O)C=C1O LTTQKYMNTNISSZ-MWTRTKDXSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- HOMSOWZTBJWNHP-UHFFFAOYSA-N 5-chlorothiadiazole Chemical compound ClC1=CN=NS1 HOMSOWZTBJWNHP-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 241001552669 Adonis annua Species 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 241000045403 Astragalus propinquus Species 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000131317 Capitulum Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241000208365 Celastraceae Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- IFYMEZNJCAQUME-APKWKYNESA-N Chrysanthemaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C1OC2(C)CC(O)CC(C)(C)C2=C1)C=CC=C(/C)C=CC3=C(C)CC(O)CC3(C)C IFYMEZNJCAQUME-APKWKYNESA-N 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 240000005250 Chrysanthemum indicum Species 0.000 description 1
- 241000737241 Cocos Species 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 240000005066 Euchiton japonicus Species 0.000 description 1
- 239000004211 Flavoxanthin Substances 0.000 description 1
- JRHJXXLCNATYLS-NGZWBNMCSA-N Flavoxanthin Chemical compound C/C([C@H]1C=C2C(C)(C)C[C@H](O)C[C@@]2(C)O1)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C JRHJXXLCNATYLS-NGZWBNMCSA-N 0.000 description 1
- QHUMOJKEVAPSCY-JOJDNVQPSA-N Flavoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C1(C)OC2(C)CC(O)CC(C)(C)C2=C1)C=CC=C(/C)C=CC3C(=CC(O)CC3(C)C)C QHUMOJKEVAPSCY-JOJDNVQPSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241001149422 Ganoderma applanatum Species 0.000 description 1
- 241001489100 Ganoderma capense Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 235000002710 Ilex cornuta Nutrition 0.000 description 1
- 241001310146 Ilex cornuta Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 108010060231 Insect Proteins Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000019926 Keshan disease Diseases 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 206010073310 Occupational exposures Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 241000904014 Pappus Species 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 240000007263 Pinus koraiensis Species 0.000 description 1
- 235000011615 Pinus koraiensis Nutrition 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 241000576755 Sclerotia Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 241000238370 Sepia Species 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 235000000336 Solanum dulcamara Nutrition 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000254223 Syntexis Species 0.000 description 1
- 241000292546 Taraxacum mongolicum Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- SZCBXWMUOPQSOX-LOFNIBRQSA-N Violaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C12OC1(C)CC(O)CC2(C)C)C=CC=C(/C)C=CC34OC3(C)CC(O)CC4(C)C SZCBXWMUOPQSOX-LOFNIBRQSA-N 0.000 description 1
- 239000004213 Violaxanthin Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010001093 acute tonsillitis Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002019 anti-mutation Effects 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- 230000003471 anti-radiation Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000019243 flavoxanthin Nutrition 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- XQVFLLMCNGKXSM-UHFFFAOYSA-N kurarinone Natural products COc1cc(O)c(C(CC=C(C)C)C(=C)C)c2OC(CC(=O)c12)c3ccc(O)cc3O XQVFLLMCNGKXSM-UHFFFAOYSA-N 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- KDADHLPROOOPIC-UHFFFAOYSA-N neokurarinol Natural products COc1cc(O)ccc1C1CC(=O)c2c(OC)cc(O)c(CC(CCC(C)(C)O)C(C)=C)c2O1 KDADHLPROOOPIC-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 231100000675 occupational exposure Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003895 organic fertilizer Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- VDYCLYGKCGVBHN-UHFFFAOYSA-N pachymaic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC(=C)C(C)C)C(O)=O)C(O)CC21C VDYCLYGKCGVBHN-UHFFFAOYSA-N 0.000 description 1
- SRDNLMOBFKJOSD-UHFFFAOYSA-N pachymic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C(O)=O)C(O)CC21C SRDNLMOBFKJOSD-UHFFFAOYSA-N 0.000 description 1
- 235000012771 pancakes Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- CEIZFXOZIQNICU-UHFFFAOYSA-N tenuazonic acid Chemical compound CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 235000019245 violaxanthin Nutrition 0.000 description 1
- SZCBXWMUOPQSOX-PSXNNQPNSA-N violaxanthin Chemical compound C(\[C@@]12[C@](O1)(C)C[C@H](O)CC2(C)C)=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/[C@]1(C(C[C@@H](O)C2)(C)C)[C@]2(C)O1 SZCBXWMUOPQSOX-PSXNNQPNSA-N 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Insects & Arthropods (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Animal Husbandry (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及药食同源食品领域,具体是一种食用组合物及其制备方法。食用组合物,按重量份计包括以下组份:灵芝60‑70份、黄芪55‑65份、人参40‑50份、茯苓40‑50份、蚕蛹25‑35份、枸杞子15‑25份、蒲公英10‑20份和炙甘草5‑15份,以灵芝和黄芪为君药,人参和茯苓为臣药,蚕蛹和枸杞子为佐药,蒲公英和炙甘草为使药,并作相宜配伍,不添加任何防腐剂、色素,无毒副作用,使用安全可靠,能够起到护肝、排毒、补气、防癌的作用;食用组合物的制备方法,经过洗净和温浸泡后,进行两次煎煮过滤,得到滤液,对滤液进行浓缩和乙醇处理得到流浸膏,将流浸膏干燥后得到食用组合物,本方法宜量产,且经过食用乙醇处理的滤液C能够充分析出各组份的药性,减少原料浪费。
Description
技术领域
本发明涉及药食同源食品领域,具体是一种食用组合物及其制备方法。
背景技术
肝是人体内最大的解毒器官,体内产生的毒物、废物,吃进去的毒物、有损肝脏的药物等等也必须依靠肝脏解毒。肝位于人体腹部右上方,承担着维持生命的重要功能。它也是人体内最大的内脏器官。肝的主要功能是分泌胆汁、储藏糖原,调节蛋白质、脂肪和碳水化合物的新陈代谢等。还有解毒、造血和凝血作用。肝解毒时由于血液在流动的关系,它不是把血液关起门来做这个工作的,而是边流动边解毒,解毒的同时身体的其他部位正常运转中还会继续产生代谢产物。所以血液里一直都会存在一些毒素,永远都解不完,只能保持我们身体的正常运转,但不能出意外和加重身体净化负担,如熬夜,酗酒,服药,感染等,否则不仅仅是肝脏解毒功能受损,别的脏器细胞也会加快老化,使体内毒素在血液中含量大大增加,这种大分子毒性物质会使血液黏稠,血流缓慢,最后停滞在人体的毛细血管中,成为“死血”。
气是运行在人体内的一种精微物质。具有极强的能量的活动力,激发和推动机体器官的功能活动,因此也代表五脏之气和经脉之气。气的作用主要是温养机体和抵御外邪的入侵,同时参与脏腑功能的新陈代谢。
癌(cancer)在医学上,是指起源于上皮组织的恶性肿瘤,是恶性肿瘤中最常见的一类。一般人们所说的“癌症”习惯上泛指所有恶性肿瘤。癌症具有细胞分化和增殖异常、生长失去控制、浸润性和转移性等生物学特征,其发生是一个多因子、多步骤的复杂过程,分为致癌、促癌、演进三个过程,与吸烟、感染、职业暴露、环境污染、不合理膳食、遗传因素密切相关。国际抗癌联盟认为,1/3的癌症是可以预防的,1/3的癌症如能早期诊断是可以治愈的,1/3的癌症可以减轻痛苦,延长生命。
在现代社会,由于生活水平的提高,以及生活压力的增大等等原因,相对应的各种疾病也随着而来,人们对于疾病的观念,预防和治疗是最主要的方式。现阶段,人们对于养生有了很大的认识,市场上各类养生产品众多,有吃的、喝的、穿的、用的等等,中医药文化是中国文化宝库中的一颗璀璨明星,是中华人民长期同疾病斗争丰富经验的总结。相关技术中,中药特别是药食同源类中药对众多疾病具有明确的预防和治疗作用,在养生产品中如果将药食同源的中药材合理的使用,并制成供人们食用的产品,预防及治疗效果定会更佳。但目前护肝、排毒、补气、防癌等方面的药食同源养生产品,其预防和治疗效果一般,且通常含有防腐剂、色素等添加剂,存在毒副作用,食用安全无法保证。
发明内容
本发明所要解决的技术问题是提供一种不添加任何防腐剂、色素,无毒副作用,食用安全可靠的具有护肝、排毒、补气、防癌功能的食用组合物及其制备方法。
本发明解决上述技术问题的技术方案如下:
一种食用组合物,按重量份计包括以下组份:灵芝60-70份、黄芪55-65份、人参40-50份、茯苓40-50份、蚕蛹25-35份、枸杞子15-25份、蒲公英10-20份和炙甘草5-15份。
进一步,各组份按重量份计优选:灵芝60份、黄芪55份、人参40份、茯苓40份、蚕蛹25份、枸杞子15份、蒲公英10份和炙甘草5份。
进一步,各组份按重量份计优选:灵芝65份、黄芪60份、人参45份、茯苓45份、蚕蛹30份、枸杞子20份、蒲公英15份和炙甘草10份。
进一步,各组份按重量份计优选:灵芝70份、黄芪65份、人参50份、茯苓50份、蚕蛹35份、枸杞子25份、蒲公英20份和炙甘草15份。
灵芝:(学名:Ganoderma Lucidum Karst):又称林中灵、琼珍,是多孔菌科真菌灵芝的子实体。主要分布于中国浙江、黑龙江、吉林、安徽、江西、湖南、贵州、广东、福建等地。性味:味甘,性平。归经:归心、脾、经。功效与主治:灵芝具有滋补强壮的功效,用于健脑、消炎、利尿、益肾、益气血,安神,健胃,止咳平喘的功效,治虚劳,头晕,心悸,失眠,消化不良,老年慢性气管炎,小儿支气管哮喘,血胆固醇过高症,冠心病,矽肺,肿瘤,白细胞减少症。灵芝应用在中国已有2000多年的历史,被历代医药家视为滋补强壮、扶正固本的神奇珍品。2000年,已知灵芝属(Ganoderma)真菌约100余种,分布最广的为赤芝(G.lu-cidum),其次为紫芝(G.japonicum),还有树舌(G.applana-tum)、松杉灵芝(G.tsugae)和簿树芝(G.capense)等均供药用。经过大量临床研究,灵芝对神经衰弱、高脂血症、冠心病心绞痛、心律失常、克山病、高原不适症、肝炎、出血热、消化不良、气管炎等各有不同程度的疗效。药理研究证明,灵芝有多方面的生物活性。主含氨基酸、多肽、蛋白质、真菌溶菌酶(fungallysozyme),以及糖类(还原糖和多糖)、麦角甾醇、三萜类、香豆精甙、挥发油、硬脂酸、苯甲酸、生物碱、维生素B2及C等;孢子还含甘露醇、海藻糖(trehalose)等。近年来人们对生活质量和保健意识的不断提高,促进了食品向功能方向发展。灵芝具有很高的天然药用价值和食用价值,用在食品上具有很好的作用,不断的为人们的生活提供更多的用处。
黄芪:属于豆科植物黄芪(Astragalus membranaceus Bge)的干燥根,主要分布于我国东部、华北、西北等地,以蒙古黄芪最有名,山西黄芪质量最好。性味甘、微温;入肺、脾经。黄芪有:生,益卫固表,利水消肿,托毒生肌;熟,补中益气。黄芪中含有黄芪多糖多种、黄芪甲甙、皂甙、黄酮、21种氨基酸、14种微量元素、蛋白质、胆碱、叶酸、亚油酸、胡萝卜素等多种成份。现代医学研究表明:黄芪具有促进细胞生长旺盛,延长细胞寿命,增强非特异性免疫,体液免疫,细胞免疫的机能;利尿作用,抗炎作用,解毒作用;延缓衰老、抗疲劳、抗应激;保护肝肾功能;抗骨质疏松;抑制流感病毒作用;改善肺脾功能,改善心脑血管功能;还有诱生干扰素的能力。
人参:(Panax ginseng C.A.Mey)为多年生草本植物,喜阴凉,叶片无气孔和栅栏组织,无法保留水分,温度高于32度叶片会灼伤,郁闭度0.7-0.8。通常3年开花,5-6年结果,花期5-6月,果期6-9月。生长于北纬33度-48度之间的海拔数百米的以红松为主的针阔混交林或落叶阔叶林下,。人参的别称为黄参、地精、神草、百草之王,是闻名遐迩的“东北三宝”之一。人参味甘、微苦,性温、平。归脾、肺经、心经。功效:大补元气,复脉固脱,补脾益肺,生津,安神。主治:体虚欲脱,肢冷脉微,脾虚食少,肺虚喘咳,津伤口渴,内热消渴,久病虚羸,惊悸失眠,阳痿宫冷;心力衰竭,心原性休克。用于气短喘促,心悸健忘,口渴多汗,食少无力,一切急慢性疾病及失血后引起的休克、虚脱。大补元气,固脱生津,安神。治劳伤虚损,食少,倦怠,反胃吐食,大便滑泄,虚咳喘促,自汗暴脱,惊悸,健忘,眩晕头痛,阳痿,尿频,消渴,妇女崩漏,小儿慢惊,及久虚不复,一切气血津液不足之证。
茯苓:为多孔菌科真菌茯苓的干燥菌核。性味甘、淡,平。入心、肺、脾、肾经。用于利水,健脾宁心。《神农本草经》:“茯苓……久服安魂养神,不饥延年。”茯苓内含有β-茯苓聚糖、茯苓酸、茯苓糖、蛋白质、葡萄糖、麦角甾醇、三萜类化合物、胆碱、组氨酸、腺嘌呤、多种酶及微量元素等。现代医学研究表明:茯苓具有增强免疫功能,抗肿瘤作用,保肝作用,降血糖作用,镇静作用,促进造血功能。
蚕蛹:具有极高的营养价值,含有丰富的蛋白质(鲜蚕蛹含粗蛋白占51%)、脂肪酸(粗脂肪占29%)、维生素(包括维生素A、维生素B2、维生素D及麦角甾醇等)。蚕蛹的蛋白质含量在50%以上,远远高于一般食品,而且蛋白质中的必需氨基酸种类齐全。蚕蛹蛋白质由18种氨基酸组成,其中人体必需的8种氨基酸含量很高。蚕蛹中的这8种人体必需的氨基酸含量大约是猪肉的2倍、鸡蛋的4倍、牛奶的10倍,且营养均衡、比例适当,是一种优质的昆虫蛋白质。蚕蛹中的氨基酸能提高免疫功能底下的小鼠的细胞免疫和体液免疫功能,免疫器官脾脏和胸腺的重量也较免疫功能低下时的小鼠增加,还能增强小鼠外周血单核吞噬细胞碳粒廊清的能力。现代医学研究表明:适量食用蚕蛹,对高血压、高血脂、慢性肝炎及营养不良患者有较好的辅助治疗功效。此外,蚕蛹中含有一种广谱免疫物质,对癌症有特殊疗效。据报道,日本等国已经从蚕蛹中生产出了α-干扰素,临床用于抗癌治疗。
枸杞子:为茄科植物宁夏枸杞(Lycium barbarum L.)的干燥成熟果实,为椭园形,干燥成品为扁平形,长1.5-2cm,直经4-8mm,橙红至暗红色,味略甜,品种较多,以宁夏枸杞果大、质佳著名。枸杞性味甘,平;日肝、肾经;有补益肝肾,养血明目的功能。枸杞中含有枸杞多糖、14种氨基酸、甜菜碱、β-胡萝卜素、β-谷甾醇、亚油酸、维生素B1、维生素B2、维生素C、色素菸酸和人体必需的微量元素等物质。现代医学研究表明:枸杞具有抗氧化,抗衰老,耐缺氧,抗疲劳,调节免疫功能,抗肿瘤,抗突变,保肝及抗脂肪肝作用,降血脂和胆固醇及抗动脉粥样硬化作用,降血糖,降血压,抗辐射及升高白细胞作用,改善造积压功能等功效。
蒲公英:(拉丁学名:Taraxacum mongolicum Hand.-Mazz.)菊科,蒲公英属多年生草本植物。根圆锥状,表面棕褐色,皱缩,叶边缘有时具波状齿或羽状深裂,基部渐狭成叶柄,叶柄及主脉常带红紫色,花葶上部紫红色,密被蛛丝状白色长柔毛;头状花序,总苞钟状,瘦果暗褐色,长冠毛白色,花果期4~10月。蒲公英别名黄花地丁、婆婆丁、华花郎等。菊科多年生草本植物。蒲公英全草含蒲公英甾醇、胆碱、菊糖、果胶等。根中含蒲公英醇、蒲公英赛醇、ψ-葡公英甾醇、蒲公英甾醇、β-香树脂醇、豆甾醇、β-谷甾醇、胆碱、有机酸、果糖、蔗糖、葡萄糖、葡萄糖甙以及树脂、橡胶等。叶含叶黄素、蝴蝶梅黄素、叶绿醌、维生素C(50~70毫克/100克)和维生素D(5~9毫克/100克)。花中含山金车二醇、叶黄素和毛莨黄素。花粉中含β-谷甾醇、5z-豆甾-7-烯-3β-醇、叶酸和维生素C。绿色花萼中含叶绿醌。花茎中含β-谷甾醇和β-香树脂醇。又该品含考迈斯托醇、核黄素1.43微克/克和胡萝卜素7.7~8.8毫克%。性味:苦甘,寒。归经:入肝、胃经。功能主治:清热解毒,利尿散结。治急性乳腺炎,淋巴腺炎,瘰疬,疔毒疮肿,急性结膜炎,感冒发热,急性扁桃体炎,急性支气管炎,胃炎,肝炎,胆囊炎,尿路感染。
甘草:为豆科植物甘草Glycyrrhiza uralensis Fisch.、胀果甘草Glycyrrhizainflata Bat.或光果甘草Glycyrrhiza glabraL.的干燥根和根茎。分布于东北、华北、陕西、甘肃、青海、新疆、山东等地。性味:味甘,性平。归经:归心、肺、脾、胃经。功效主治:补脾益气,清热解毒,祛痰止咳,缓急止痛,调和诸药。用于脾胃虚弱,倦怠乏力,心悸气短,咳嗽痰多,脘腹、四肢挛急疼痛,痈肿疮毒,缓解药物毒性、烈性,遂有国老之号。”陶弘景称之为“诸药之王”,“国老即帝师之称,虽非君而为君所宗”。李时珍说:“甘草协和群品,有元老之功,普治百邪,得王道之化,可谓药之良相也。”炙甘草是用蜜烘制的甘草。
本组合物以灵芝和黄芪为君药,人参和茯苓为臣药,蚕蛹和枸杞子为佐药,蒲公英和炙甘草为使药,并作相宜配伍,不添加任何防腐剂、色素,无毒副作用,使用安全可靠,能够起到护肝、排毒、补气、防癌的作用,对现代人群健康状况起到显著的食疗效果。
本发明还提供了上述食用组合物的制备方法,包括以下步骤:
1)按重量份取所述灵芝、黄芪、人参、伏苓、蚕蛹、枸杞子、蒲公英和炙甘草洗净,温水浸泡50-70分钟后取出,得到混合组份;
2)取所述混合组份用6倍量的水煎煮110-130分钟,用100目筛过滤,得滤液A和滤渣A,而后取所述滤渣A用5倍量的水煎煮50-70分钟,用100目筛过滤,得滤液B和滤渣B;
3)取所滤液A和滤液B混合,用100目筛过滤,得到滤液C和滤渣C;
4)取所述滤液C浓缩至相对密度1.06-1.10,而后加入食用乙醇使所述滤液C的醇含量达到69%-71%后在4-6℃温度环境下冷藏23-25小时得到分层液,取所述分层液的上清液经过100目筛过滤后浓缩至相对密度1.06-1.10,得到流浸膏;
5)将所述流浸膏干燥后得到干浸膏,即食用组合物。
进一步,步骤1)中,各组份取用5倍量水洗净。确保充分洗净各组份。
进一步,步骤4)中,冷藏环境为4-6℃温度环境,冷藏时长为23-25小时。确保得到的分层液层次明确,分层清楚。
进一步,步骤4)中,从所述分层液取走上清液后回收食用乙醇。提升食用乙醇利用率,避免原料浪费。
进一步,步骤5)中,所述流浸膏在80-90℃的温度环境下干燥5-6小时得到所述干浸膏。确保流浸膏干燥充分。
进一步,取所述干浸膏粉碎后经过200目筛,得到粉末后制作口服制剂。厂家可以根据目标用户群体生产适宜的口服制剂,例如:可以是散剂、颗粒剂、粉剂、口服液、丸剂等;也可将其制备成保健食品或食品;且可按个人喜好添加蜂蜜或蔗糖进行口感的调节。
本方法步骤简单,适宜量产,且经过食用乙醇处理的滤液C能够充分析出各组份的药性,有效减少原料浪费,另外,产生的滤渣B和滤渣C可用于喂养牲畜或作为有机肥料用于果树栽培,物尽其用。
具体实施方式
下面将对本发明技术方案的实施例进行详细的描述。以下实施例仅用于更加清楚地说明本发明的技术方案,因此只作为示例,而不能以此来限制本发明的保护范围。
实施例1
一种食用组合物,按重量克计包括以下组克:灵芝60克、黄芪55克、人参40克、茯苓40克、蚕蛹25克、枸杞子15克、蒲公英10克和炙甘草5克。
上述食用组合物的制备方法包括以下步骤:
1)按重量克取灵芝、黄芪、人参、伏苓、蚕蛹、枸杞子、蒲公英和炙甘草用5倍量水洗净,温水浸泡50分钟后取出,得到混合组份;
2)取所述混合组份用6倍量的水煎煮110分钟,用100目筛过滤,得滤液A和滤渣A,而后取所述滤渣A用5倍量的水煎煮50分钟,用100目筛过滤,得滤液B和滤渣B;
3)取所滤液A和滤液B混合,用100目筛过滤,得到滤液C和滤渣C;
4)取所述滤液C浓缩至相对密度1.06-1.10,而后加入食用乙醇使所述滤液C的醇含量达到70%后在5℃温度环境下冷藏24小时得到分层液,取所述分层液的上清液经过100目筛过滤后浓缩至相对密度1.06-1.10,得到流浸膏。
5)将所述流浸膏干燥后得到干浸膏,即食用组合物,取所述干浸膏粉碎后经过200目筛,得到粉末后制作口服制剂。
优选地,步骤4)中,从所述分层液取走上清液后回收食用乙醇。
优选地,步骤5)中,所述流浸膏在80℃的温度环境下干燥6小时得到所述干浸膏。
实施例2
一种食用组合物,按重量克计包括以下组克:灵芝65克、黄芪60克、人参45克、茯苓45克、蚕蛹30克、枸杞子20克、蒲公英15克和炙甘草10克。
上述食用组合物的制备方法包括以下步骤:
1)按重量克取灵芝、黄芪、人参、伏苓、蚕蛹、枸杞子、蒲公英和炙甘草用5倍量水洗净,温水浸泡50-70分钟后取出,得到混合组份;
2)取所述混合组份用6倍量的水煎煮120分钟,用100目筛过滤,得滤液A和滤渣A,而后取所述滤渣A用5倍量的水煎煮60分钟,用100目筛过滤,得滤液B和滤渣B;
3)取所滤液A和滤液B混合,用100目筛过滤,得到滤液C和滤渣C;
4)取所述滤液C浓缩至相对密度1.06-1.10,而后加入食用乙醇使所述滤液C的醇含量达到70%后在5℃温度环境下冷藏24小时得到分层液,取所述分层液的上清液经过100目筛过滤后浓缩至相对密度1.06-1.10,得到流浸膏。
5)将所述流浸膏干燥后得到干浸膏,即食用组合物,取所述干浸膏粉碎后经过200目筛,得到粉末后制作口服制剂。
优选地,步骤4)中,从所述分层液取走上清液后回收食用乙醇。
优选地,步骤5)中,所述流浸膏在85℃的温度环境下干燥5.5小时得到所述干浸膏。
实施例3
一种食用组合物,按重量克计包括以下组克:灵芝70克、黄芪65克、人参50克、茯苓50克、蚕蛹35克、枸杞子25克、蒲公英20克和炙甘草15克。
上述食用组合物的制备方法包括以下步骤:
1)按重量克取灵芝、黄芪、人参、伏苓、蚕蛹、枸杞子、蒲公英和炙甘草用5倍量水洗净,温水浸泡70分钟后取出,得到混合组份;
2)取所述混合组份用6倍量的水煎煮130分钟,用100目筛过滤,得滤液A和滤渣A,而后取所述滤渣A用5倍量的水煎煮70分钟,用100目筛过滤,得滤液B和滤渣B;
3)取所滤液A和滤液B混合,用100目筛过滤,得到滤液C和滤渣C;
4)取所述滤液C浓缩至相对密度1.06-1.10,而后加入食用乙醇使所述滤液C的醇含量达到70%后在5℃温度环境下冷藏24小时得到分层液,取所述分层液的上清液经过100目筛过滤后浓缩至相对密度1.06-1.10,得到流浸膏。
5)将所述流浸膏干燥后得到干浸膏,即食用组合物,取所述干浸膏粉碎后经过200目筛,得到粉末后制作口服制剂。
优选地,步骤4)中,从所述分层液取走上清液后回收食用乙醇。
优选地,步骤5)中,所述流浸膏在90℃的温度环境下干燥5小时得到所述干浸膏。
实施例4
一种食用组合物,按重量克计包括以下组克:灵芝65克、黄芪60克、人参50克、茯苓45克、蚕蛹35克、枸杞子20克、蒲公英20克和炙甘草15克。
上述食用组合物的制备方法包括以下步骤:
1)按重量克取灵芝、黄芪、人参、伏苓、蚕蛹、枸杞子、蒲公英和炙甘草用5倍量水洗净,温水浸泡60分钟后取出,得到混合组份;
2)取所述混合组份用6倍量的水煎煮120分钟,用100目筛过滤,得滤液A和滤渣A,而后取所述滤渣A用5倍量的水煎煮70分钟,用100目筛过滤,得滤液B和滤渣B;
3)取所滤液A和滤液B混合,用100目筛过滤,得到滤液C和滤渣C;
4)取所述滤液C浓缩至相对密度1.06-1.10,而后加入食用乙醇使所述滤液C的醇含量达到70%后在5℃温度环境下冷藏24小时得到分层液,取所述分层液的上清液经过100目筛过滤后浓缩至相对密度1.06-1.10,得到流浸膏。
5)将所述流浸膏干燥后得到干浸膏,即食用组合物,取所述干浸膏粉碎后经过200目筛,得到粉末后制作口服制剂。
优选地,步骤4)中,从所述分层液取走上清液后回收食用乙醇。
优选地,步骤5)中,所述流浸膏在90℃的温度环境下干燥5小时得到所述干浸膏。
实施例5
一种食用组合物,按重量克计包括以下组克:灵芝70克、黄芪60克、人参40克、茯苓40克、蚕蛹35克、枸杞子20克、蒲公英20克和炙甘草10克。
上述食用组合物的制备方法包括以下步骤:
1)按重量份取灵芝、黄芪、人参、伏苓、蚕蛹、枸杞子、蒲公英和炙甘草用5倍量水洗净,温水浸泡60分钟后取出,得到混合组份;
2)取所述混合组份用6倍量的水煎煮120分钟,用100目筛过滤,得滤液A和滤渣A,而后取所述滤渣A用5倍量的水煎煮60分钟,用100目筛过滤,得滤液B和滤渣B;
3)取所滤液A和滤液B混合,用100目筛过滤,得到滤液C和滤渣C;
4)取所述滤液C浓缩至相对密度1.06-1.10,而后加入食用乙醇使所述滤液C的醇含量达到70%后在5℃温度环境下冷藏24小时得到分层液,取所述分层液的上清液经过100目筛过滤后浓缩至相对密度1.06-1.10,得到流浸膏。
5)将所述流浸膏干燥后得到干浸膏,即食用组合物,取所述干浸膏粉碎后经过200目筛,得到粉末后制作口服制剂。
优选地,步骤4)中,从所述分层液取走上清液后回收食用乙醇。
优选地,步骤5)中,所述流浸膏在90℃的温度环境下干燥5小时得到所述干浸膏。
试验例1:实施例1-5食用组合物护肝效果的临床疗效应用试验
用于350例长期饮酒人群、脂肪肝、酒精肝、农药及抗生素与激素化学有害物质所致药物性肝损伤和肝硬化、肝癌各种慢性肝病患者(男性230例,女性120例,平均年龄52岁),均分为5组,试验1组服用实施例1的食用组合物,试验2组服用实施例2的食用组合物,试验组3组服用实施例3的食用组合物,试验4组服用实施例4的食用组合物,试验组5服用实施例5的食用组合物。5组患者食用剂量和次数相同情况下的临床观察结果详见表1.
表1本发明食用组合物的临床疗效观察试验结果
临床疗效观察结果表明,实施例1-5食用组合物组对于肝疾病具有显著的疗效;总有效率达82%以上,说明本发明食用组合物可明显改善因长期饮酒人群、脂肪肝、酒精肝、农药及抗生素与激素化学有害物质所致药物性肝损伤和肝硬化、肝癌各种慢性肝病患者症状。
安全性观察发现,没有观察到任何临床不良反应,表明本发明食用组合物临床应用安全、无毒副作用。
试验例2:本发明组合物对护肝、排毒、补气、防癌的临床疗效试验典型病例
典型例1:张某某,男,年龄50岁,广东省梅县区人,由于长期饮酒抽烟,饮食长期摄入脂肪过多导致酒精肝,并伴有困倦无力,眼白发黄,小便黄色,早上起床口苦。在食用实施例1食用组合物,每次1袋,每日3次用开水冲服,连续食用10天后,小便颜色转为正常,早起口不苦;连续食用20天后临床症状基本症状基本消失,眼白颜色恢复正常,精神状态良好;再服用15天后,症状全部消失,肝功能恢复正常,精神饱满。
典型例2:刘某某,女,年龄55岁,广东省五华县人,由于30岁体检查出患有乙肝,无正规治疗也无进行复查,直至出现肝区疼痛进院检查,检查结果为原发性肝癌Ⅰa期,在半肝处有1个1.03厘米肿瘤。临床症状为肝区疼痛为间歇持续性钝痛,伴有恶心轻微腹泻,乏力困倦,体型消瘦,甲胎蛋白AFP为69.47ng/ml。多家医院治疗后只能稳定,无实质性改善。在食用实施例2食用组合物,每次1袋,每日3次开水冲服,连续食用15天后临床症状明显改善,恶心腹泻消失,胃口转好。再食用30天后肝区不疼,脸上红润,精气神较好。复检甲胎蛋白AFP为26.32ng/ml,再食用30天后甲胎蛋白AFP为10.06ng/ml,接近正常值。肿瘤为0.32厘米,临床症状基本消失。
典型例3:陈某某,女,38岁,广东省梅江区人,由于自身抗体阴性,感染慢性乙型肝炎,导致食欲不振、厌油、上腹部不适、眼白变黄、脸部气色差经常长痘痘、体型消瘦。检查显示ALT及胆红素升高,精氨酸琥珀酸裂解酶(ASAL)、碱性磷酸酶也升高。在食用实施例3,每次1袋,每日3次用开水冲服,连续食用15天后,食欲改善,眼白正常;连续食用30天后临床症状基本症状消失,脸部气色好不长痘痘,复查肝功能各项数值正常。
最后应说明的是:以上各实施例仅用以说明本发明的技术方案,而非对其限制;尽管参照前述各实施例对本发明进行了详细的说明,本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分或者全部技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各实施例技术方案的范围,其均应涵盖在本发明的权利要求和说明书的范围当中。
Claims (10)
1.一种食用组合物,其特征在于,按重量份计包括以下组份:灵芝60-70份、黄芪55-65份、人参40-50份、茯苓40-50份、蚕蛹25-35份、枸杞子15-25份、蒲公英10-20份和炙甘草5-15份。
2.根据权利要求1所述的食用组合物,其特征在于,各组份按重量份计优选:灵芝60份、黄芪55份、人参40份、茯苓40份、蚕蛹25份、枸杞子15份、蒲公英10份和炙甘草5份。
3.根据权利要求1所述的食用组合物,其特征在于,各组份按重量份计优选:灵芝65份、黄芪60份、人参45份、茯苓45份、蚕蛹30份、枸杞子20份、蒲公英15份和炙甘草10份。
4.根据权利要求1所述的食用组合物,其特征在于,各组份按重量份计优选:灵芝70份、黄芪65份、人参50份、茯苓50份、蚕蛹35份、枸杞子25份、蒲公英20份和炙甘草15份。
5.一种如权利要求1-4任一项所述的食用组合物的制备方法,其特征在于,包括以下步骤:
1)按重量份取所述灵芝、黄芪、人参、伏苓、蚕蛹、枸杞子、蒲公英和炙甘草洗净,温水浸泡50-70分钟后取出,得到混合组份;
2)取所述混合组份用6倍量的水煎煮110-130分钟,用100目筛过滤,得滤液A和滤渣A,而后取所述滤渣A用5倍量的水煎煮50-70分钟,用100目筛过滤,得滤液B和滤渣B;
3)取所滤液A和滤液B混合,用100目筛过滤,得到滤液C和滤渣C;
4)取所述滤液C浓缩至相对密度1.06-1.10,而后加入食用乙醇使所述滤液C的醇含量达到69%-71%后冷藏得到分层液,取所述分层液的上清液经过100目筛过滤后浓缩至相对密度1.06-1.10,得到流浸膏;
5)将所述流浸膏干燥后得到干浸膏,即食用组合物。
6.根据权利要求5所述的食用组合物的制备方法,其特征在于,步骤1)中,各组份取用5倍量水洗净。
7.根据权利要求5所述的食用组合物的制备方法,其特征在于,步骤4)中,冷藏环境为4-6℃温度环境,冷藏时长为23-25小时。
8.根据权利要求5所述的食用组合物的制备方法,其特征在于,步骤4)中,从所述分层液取走上清液后回收食用乙醇。
9.根据权利要求5所述的食用组合物的制备方法,其特征在于,步骤5)中,所述流浸膏在80-90℃的温度环境下干燥5-6小时得到所述干浸膏。
10.根据权利要求5所述的食用组合物的制备方法,其特征在于,取所述干浸膏粉碎后经过200目筛,得到粉末后制作口服制剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910440842.1A CN110075188A (zh) | 2019-05-24 | 2019-05-24 | 食用组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910440842.1A CN110075188A (zh) | 2019-05-24 | 2019-05-24 | 食用组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110075188A true CN110075188A (zh) | 2019-08-02 |
Family
ID=67421761
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910440842.1A Withdrawn CN110075188A (zh) | 2019-05-24 | 2019-05-24 | 食用组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110075188A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110934957A (zh) * | 2019-12-30 | 2020-03-31 | 颜振清 | 药食同源的富硒锌微量元素保肝护肝饮品及制备工艺 |
-
2019
- 2019-05-24 CN CN201910440842.1A patent/CN110075188A/zh not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110934957A (zh) * | 2019-12-30 | 2020-03-31 | 颜振清 | 药食同源的富硒锌微量元素保肝护肝饮品及制备工艺 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101695376B (zh) | 预防糖尿病的保健食品 | |
CN103053748B (zh) | 一种葛根降脂降糖保健茶及其制备方法 | |
CN100374538C (zh) | 五脏滋补酒及其制备工艺 | |
CN103734428B (zh) | 一种提高免疫力的女贞子保健茶及其制备方法 | |
CN107929420A (zh) | 改善人体气血功能和提高免疫力的中药组合物和检测方法 | |
CN108524814A (zh) | 一种用于降低血糖的中药组合物及其制备方法 | |
CN106359720A (zh) | 一种清咽利喉和润肺清火的保健茶及其制备方法 | |
CN105454576A (zh) | 茉莉花八宝茶及其制备方法 | |
CN103301413A (zh) | 一种治疗高血脂合并高血糖症的中药组合物 | |
CN103690784B (zh) | 治疗糖尿病肾病合并高血压肾病的中药组合物及制备方法 | |
CN102860390B (zh) | 一种桑叶减肥茶及其制备方法 | |
CN104083640B (zh) | 一种治疗糖尿病的中药组合物及其制备方法 | |
CN110075188A (zh) | 食用组合物及其制备方法 | |
CN107125751B (zh) | 龟粉、制备方法及其应用 | |
CN104825821A (zh) | 一种治疗糖尿病的药物及其制备方法 | |
CN104771462A (zh) | 一种治疗慢性支气管炎的中药及其制备方法 | |
CN114748603A (zh) | 一种防治新冠病毒肺炎变异或复阳的药食同源组合物和应用 | |
CN107712890A (zh) | 一种宁心安神膏滋及其制备方法 | |
CN113826882A (zh) | 防治糖尿病的膳食营养补充剂及其制备工艺 | |
CN109718305A (zh) | 改善人体气血功能提高耐缺氧延缓衰老的中药组合物 | |
CN104784472A (zh) | 一种降血糖治疗糖尿病的中药组合物 | |
CN107519429B (zh) | 具有改善脾胃和促进通便排毒功能的中药组合物及制法 | |
CN108310212A (zh) | 一种用于延缓衰老的药物及其制备方法和应用 | |
CN104524359B (zh) | 一种中药组合物、其制备方法及应用 | |
CN108893222A (zh) | 一种壮乡露酒及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20190802 |
|
WW01 | Invention patent application withdrawn after publication |